Proton Therapy in the Treatment of Liver Metastases
| Status: | Recruiting |
|---|---|
| Conditions: | Liver Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/27/2019 |
| Start Date: | September 2012 |
| End Date: | September 2026 |
| Contact: | Bernadette Bautista, RN |
| Email: | bbautista@llu.edu |
| Phone: | 800-496-4966; 909-558-4000 |
Phase I-II Trial of Stereotactic Body Proton Therapy for Patients With Liver Metastases
Local control of hepatic metastases appears to be a major determinant of overall survival.
However, many patients are not suitable for resection due to medical or surgical reasons.
Therefore, there is an important role for a treatment that can provide the equivalent of
tumor resection with minimal morbidity. Stereotactic body radiotherapy (SBRT) delivers an
ablative regimen of highly focused external beam radiotherapy that targets one or more
discrete extracranial lesions. Published reports using SBRT to treat liver metastases have
shown actuarial local control rates ranging from 50-100% with higher doses associated with
better local control.
In patients with metastatic liver disease, aggressive local therapy using modern radiotherapy
techniques are promising and project to have a substantial role in the treatment of
metastatic liver cancer to treat unresectable disease. The dosimetric advantage of proton
therapy may lead to improved clinical outcomes with less morbidity, however, there is no
clinical data to confirm this assertion. We thus propose a phase I study to determine the
feasibility and safety of stereotactic body proton therapy in patients with liver metastases
followed by a phase II study to determine the efficacy of such treatment on local control.
However, many patients are not suitable for resection due to medical or surgical reasons.
Therefore, there is an important role for a treatment that can provide the equivalent of
tumor resection with minimal morbidity. Stereotactic body radiotherapy (SBRT) delivers an
ablative regimen of highly focused external beam radiotherapy that targets one or more
discrete extracranial lesions. Published reports using SBRT to treat liver metastases have
shown actuarial local control rates ranging from 50-100% with higher doses associated with
better local control.
In patients with metastatic liver disease, aggressive local therapy using modern radiotherapy
techniques are promising and project to have a substantial role in the treatment of
metastatic liver cancer to treat unresectable disease. The dosimetric advantage of proton
therapy may lead to improved clinical outcomes with less morbidity, however, there is no
clinical data to confirm this assertion. We thus propose a phase I study to determine the
feasibility and safety of stereotactic body proton therapy in patients with liver metastases
followed by a phase II study to determine the efficacy of such treatment on local control.
Inclusion Criteria:
Pathologically confirmed non-lymphoma liver metastases or
New radiographic liver lesions consistent with metastases in patients with known
pathologically confirmed non-lymphoma cancer
1-3 liver lesions measurable on CT/MRI or PET/CT performed within 6 weeks prior to study
entry
Liver metastases measuring <5cm
Life expectancy >6 months
Disease outside the liver is allowed
Age ≥ 18
ECOG Performance Scale = 0-1
Adequate bone marrow function, defined as follows:
- Absolute neutrophil count (ANC) ≥ 1,000 cells/mm3 based upon CBC/differential obtained
within 4 weeks prior to registration on study
- Platelets ≥ 60,000 cell/mm3 based upon CBC/differential obtained within 4 weeks prior
to registration on study
- Hemoglobin ≥ 8.0 g/dl based upon CBC/differential obtained within 4 weeks prior to
registration on study (Note: the use of transfusion or other intervention to achieve
Hgb ≥ 8.0 is acceptable.)
Adequate kidney function (serum creatinine <2mg/dL) based on chemistry panel obtained
within 4 weeks prior to registration on study
Adequate liver function, defined as total bilirubin <5 mg/dL, serum albumin >2.0g/dL, serum
levels of liver enzymes < 5 times the upper limit of normal, and INR < 1.5
Previous liver resection or ablative therapy is permitted
Chemotherapy and/or targeted agent therapy must be completed at least 2 weeks prior to
radiation and started at least 14 days after completion of SBPT Women of childbearing
potential and male participants must practice adequate contraception
Patient must sign study specific informed consent prior to study entry
Pretreatment evaluations required for eligibility include:
- A complete history and general physical examination
- For women of childbearing potential, a serum or urine pregnancy test must be performed
within 72 hours prior to registration
- INR, total bilirubin, albumin, alkaline phosphatase, ALT, AST within 4 weeks prior to
study entry
Exclusion Criteria:
Prior invasive malignancy other than liver met primary (except non-melanomatous skin
cancer) unless disease free for > 3years
Prior radiotherapy that would results in overlap of radiation fields
Prior radiotherapy to the liver
Severe, active co-morbidity that may impact survival
CNS metastases
Tense ascites requiring frequent paracentesis
Active liver infection
Pregnancy, nursing women, or women of child bearing potential, and men who are sexually
active and not willing/able to use medically acceptable forms of contraception
Metastases location within 2cm of GI tract
We found this trial at
1
site
11234 Anderson St
Loma Linda, California 92354
Loma Linda, California 92354
(909) 558-4000
Principal Investigator: Gary Yang, MD
Phone: 800-776-8667
Loma Linda University Medical Center An outgrowth of the original Sanitarium on the hill in...
Click here to add this to my saved trials
